Actively managed fund

Janus Henderson Hrzn Biotec H2 USD

ISIN
LU1897414485
Minimum investment
7,500 USD

How good is this fund, really?

See the rating in the app

About Janus Henderson Hrzn Biotec H2 USD

Biotechnology is the single sector of Janus Henderson Horizon Biotechnology Fund, a Luxembourg SICAV sub-fund managed by Janus Henderson Investors Europe S.A. At least 80% of assets go into biotech or biotech-related shares worldwide, smaller companies included, with a possible tilt to firms whose products are still in development. The team targets innovative companies tackling high unmet medical needs that trade well below estimated intrinsic value, using statistical models of clinical success plus physician surveys, prescription models and scenario analysis. The aim: beat the NASDAQ Biotechnology Total Return Index by 2% a year, before charges, over any five years. This US dollar H2 class, launched in December 2018, accumulates income and charges 1.24% a year. Risk: 6 of 7. Recommended horizon: five years or more.

Watch this fund for free Add Janus Henderson Hrzn Biotec H2 USD to your watchlist in the PowerFunds app and we tell you when it falls behind the rest of its category.

Watch the fund for free

Where to buy Janus Henderson Hrzn Biotec H2 USD — platforms and fees

Sold on one platform we follow.

Janus Henderson Hrzn Biotec H2 USD — its category

Sector Equity Biotechnology — PowerFunds rates 55 funds in this category every month.

Biotechnology funds →

Other funds